CPT® Code 82553

Quick Reference

• Code definition: Reports measurement of the CK-MB fraction only, performed via chemiluminescent immunoassay on a serum specimen; the venipuncture is separately reportable.
• Key billing rule: MUE = 3; serial draws on the same date of service require Modifier 91 on each unit after the first. Do not exceed three units per date without additional documentation.
• Modifier essentials: Modifier 91 for serial same-day draws in ACS protocols; Modifier 59 when 82553 and 82550 are both medically necessary and separately performed on the same date. Do not append Modifier QW; 82553 is not CLIA-waived.
• Documentation must-have: A valid physician order with a documented clinical indication (chest pain, suspected ACS, post-surgical cardiac monitoring) is required before the laboratory performs the test.
• Top confusion point: Do not report 82552 (isoenzymes) when the lab measured only the MB fraction. 82552 requires electrophoretic separation and reporting of multiple fractions (MM, MB, BB); billing 82552 when only the MB result exists constitutes upcoding.
• Payer alert: 82553 carries a Statutory Exclusion from the Medicare Physician Fee Schedule; payment routes through the Clinical Laboratory Fee Schedule (CLFS), not MPFS. In hospital outpatient settings, the APC status is "Conditionally Packaged," meaning the test may be bundled into a higher-level APC when a significant procedure occurs on the same date.
• CLIA requirement: 82553 is not CLIA-waived. Laboratories performing this test must hold at minimum a CLIA Certificate of Compliance for moderate complexity testing [1].

When to Use This Code

CK-MB is a cardiac-specific isoenzyme released into the bloodstream when myocardial cells are injured or necrotic. After acute myocardial infarction (AMI), CK-MB rises within 3 to 6 hours of symptom onset, peaks at 12 to 24 hours, and returns to baseline within 48 to 72 hours. This narrower kinetic window compared to troponin is CK-MB's primary clinical advantage for reinfarction detection: when troponin remains persistently elevated from an initial event, a re-elevation of CK-MB after return to normal signals a new infarction. That specific use case continues to justify CK-MB testing even as high-sensitivity troponin has become the preferred primary biomarker for ACS diagnosis.

Report 82553 in these clinical settings:

• Evaluation of suspected AMI or acute coronary syndrome (ACS) when the laboratory performs a direct CK-MB immunoassay (not full isoenzyme separation)
• Serial cardiac biomarker panels in ED or inpatient ACS rule-out protocols (0, 6, and 12-hour draws)
• Detection of reinfarction in patients whose troponin remains elevated from a prior event
• Post-cardiac surgery monitoring for perioperative MI (e.g., post-CABG)
• Cardiac contusion assessment following chest trauma
• Elevated total CK workup where the clinician needs to determine whether the source is cardiac versus skeletal muscle

Setting and provider context: 82553 is ordered most frequently in the emergency department and inpatient settings. There is no professional/technical component split (PC/TC indicator = 9), so Modifier 26 and TC do not apply. The ordering provider documents clinical necessity; the laboratory bills under its CLIA certification.

Code Differentiation Table

The critical distinction between 82553 and 82552 is the laboratory method, not the ordering intent. If the lab report shows only a CK-MB value (numeric result from immunoassay), report 82553. If the lab report shows percentage fractions for CK-MM, CK-MB, and CK-BB from electrophoretic separation, report 82552. Confirm with the lab's test requisition or result report before code selection.

flowchart TD
    A[CK test ordered] --> B{What did the lab measure?}
    B --> C[Total CK only]
    B --> D[MB fraction only via immunoassay]
    B --> E[MM% plus MB% plus BB% via electrophoresis]
    B --> F[Isoform subtypes MM1/MM2/MB1/MB2]
    C --> G[82550]
    D --> H[82553]
    E --> I[82552]
    F --> J[82554]

Billing & Modifier Rules

Modifier 91 for serial testing: The standard ACS biomarker protocol involves draws at 0, 6, and 12 hours. When three CK-MB values are obtained on the same date of service, report 82553 for the first draw, then 82553 with Modifier 91 for each subsequent draw. The MUE of 3 accommodates up to three units per date [1]. Do not use Modifier 91 when a rerun is performed to confirm an initial result, resolve a specimen problem, or satisfy quality control requirements.

Modifier 59 with 82550: When total CK (82550) and MB fraction (82553) are both independently ordered and performed on the same date, they may be separately reportable. Verify NCCI PTP edit status between these two codes for the billing payer; some payers allow both when separately ordered, while others may require Modifier 59 to distinguish the distinct clinical purpose. Do not use Modifier 59 to bypass legitimate bundling.

Do not append Modifier QW: 82553 is not CLIA-waived [1]. Appending QW is incorrect and could generate false waiver claims, which carries compliance risk beyond a simple billing error.

Modifiers 26/TC/50/51: Not applicable. The PC/TC indicator is 9 (concept does not apply), and bilateral surgery and multiple procedure concepts do not apply to laboratory codes.

APC bundling in hospital outpatient settings: Under OPPS, 82553 carries an APC status of "Conditionally Packaged." When performed alongside a significant procedure on the same outpatient date, the lab test may be packaged into the higher-level APC rather than paid separately. Hospital outpatient billers must account for this packaging logic in ED and ambulatory claims.

MUE summary:

Documentation Essentials

Required elements: The medical record must contain a valid physician order with a documented clinical indication before the laboratory performs the test. Acceptable indications include chest pain with cardiac risk factors, suspected ACS, post-cardiac surgery monitoring, and evaluation of elevated total CK for cardiac versus skeletal muscle source. The ordering provider does not need to document the CPT code, but must establish medical necessity traceable to the claim's supporting diagnosis.

For serial testing with Modifier 91: Documentation must reflect a distinct clinical reason for each repeat measurement. For ACS protocols, the record should document the time-point structure (e.g., "serial troponin and CK-MB at 0, 6, 12 hours per ACS protocol"). If audited, the time-points and clinical context of each draw must be individually traceable in the record.

ABN for Medicare patients: If medical necessity is questionable (e.g., CK-MB ordered reflexively in a low-risk patient without chest pain or documented cardiac history), an Advance Beneficiary Notice (ABN) should be obtained prior to specimen collection.

Audit red flags specific to 82553:

• CK-MB ordered without documented chest pain, ACS symptoms, or cardiac monitoring indication in the encounter note or order
• Serial draws billed with Modifier 91 without time-stamped documentation of each individual draw
• 82552 billed when the lab report shows only a single CK-MB numeric value
• QW modifier appended despite non-waived CLIA status

Medicare, Commercial & Medicaid Payer Rules

Medicare:

82553 is excluded from the Medicare Physician Fee Schedule (Statutory Exclusion) and is payable under the Clinical Laboratory Fee Schedule (CLFS) [1]. Payment rates are set annually by CMS under the Protecting Access to Medicare Act (PAMA) methodology. For coverage criteria, search the CMS Medicare Coverage Database for active local coverage determinations (LCDs) applicable to cardiac biomarkers under your MAC jurisdiction. LCDs may define covered ICD-10-CM diagnoses and frequency limitations beyond the acute presentation setting. Commonly supported diagnoses include acute myocardial infarction (I21.x), chest pain (R07.9), myocarditis (I40.x), and cardiac monitoring post-procedure (I97.190, Z48.812).

The MUE of 3 is enforced at the claim level [1]. Exceeding it without Modifier 91 and supporting documentation will result in denial of excess units.

Commercial payers:

Commercial coverage policies generally follow Medicare medical necessity standards for CK-MB but may carry payer-specific frequency restrictions or panel bundling rules. Some commercial payers automate bundling of CK-MB with troponin orders under cardiac biomarker panel logic; verify whether contracted payers require a specific panel code or allow individual component billing. Prior authorization is not typically required for routine cardiac biomarker testing in the ED or inpatient setting, but verify for outpatient laboratory orders in non-acute scenarios.

Hospital outpatient (OPPS):

The conditionally packaged APC status requires hospital outpatient billing staff to verify whether 82553 is packaged into a concurrent significant procedure APC on any given encounter. When packaged, the test does not generate a separate APC payment; when no significant procedure is present, it is paid independently. This distinction is material for ED claims involving both cardiac workup labs and procedures performed during the same visit.

Common Denials & Prevention

Insufficient medical necessity

CK-MB ordered without a documented cardiac indication in the medical record. Payers following LCD criteria will deny claims where the supporting diagnosis does not align with covered indications, particularly for outpatient non-acute orders.

Prevention: The ordering provider must document the clinical indication in the order or encounter note before the test is performed. Diagnoses such as R07.9 (chest pain, unspecified) or I21.4 (NSTEMI) must match the documented clinical context. For low-risk patients where coverage is uncertain, obtain an ABN before specimen collection.

MUE exceeded without Modifier 91

Multiple units of 82553 billed on the same date without Modifier 91 on subsequent units, causing units 2 and 3 to deny against the per-line MUE.

Prevention: Apply Modifier 91 to units 2 and 3 when serial draws are performed on the same date. The record must document the distinct time-points for each draw. Four or more CK-MB draws on a single date exceed the MUE of 3 regardless of modifier use and will require medical review.

Upcoding: 82552 billed when 82553 is correct

This error may not generate an immediate automated denial but surfaces during audit. Reviewers comparing lab reports against billed codes will identify claims where only a CK-MB numeric value appears in the report while 82552 (isoenzymes) was billed.

Prevention: Confirm the billed code against the lab's test requisition and result report. A single CK-MB value from immunoassay equals 82553. Electrophoretic fractionation reporting CK-MM%, CK-MB%, and CK-BB% equals 82552. Never select the code based on the order description alone.

Modifier QW applied incorrectly

QW appended to 82553 indicating CLIA-waived status when the code is not CLIA-waived [1].

Prevention: Remove QW from 82553 claims. Applying QW to a non-waived test is a compliance issue that extends beyond a billing correction; it may constitute a false claim under the CLIA waiver program.

Claim routed to MPFS instead of CLFS

82553 submitted under Part B physician/professional fee schedule rather than the Clinical Laboratory Fee Schedule.

Prevention: Route laboratory claims through the appropriate billing pathway. All CK/CPK codes carry Statutory Exclusion from MPFS [1]. Independent labs bill under CLFS; hospital labs bill under OPPS revenue codes. Physician office labs must use the correct claim type for standalone lab billing.

Coding Scenarios

Scenario 1: Serial ACS rule-out in the emergency department

A 58-year-old male presents with substernal chest pain and diaphoresis. The physician orders serial cardiac biomarkers at arrival, 6 hours, and 12 hours. The lab performs chemiluminescent immunoassay reporting only CK-MB values at each draw, along with quantitative troponin.

Correct coding: 82553 (draw 1), 82553-91 (draw 2), 82553-91 (draw 3); plus 84484 with corresponding units and Modifier 91. Supporting diagnosis: R07.9 at presentation, updating to I21.4 if NSTEMI is confirmed.

Why: Only the MB fraction was measured at each time point; 82552 would be incorrect because no electrophoretic isoenzyme separation was performed. The MUE of 3 accommodates all three same-day units with Modifier 91 on the repeat draws.

Scenario 2: Reinfarction detection, inpatient day 4

A 72-year-old patient admitted for confirmed NSTEMI has persistently elevated troponin by day 3, as expected. On day 4, new chest pain develops and the cardiologist orders CK-MB specifically to evaluate for reinfarction, because troponin cannot signal a new event while still elevated from the initial infarct.

Correct coding: 82553 on day 4 with I22.2 (subsequent STEMI, inferior) or the appropriate I22.x if reinfarction is confirmed; I21.4 if still evaluating.

Why: This is a different date of service; Modifier 91 is not needed. The medical record should document why CK-MB was selected over repeat troponin, establishing reinfarction detection as the specific clinical rationale. That documentation protects against medical necessity denial when troponin was already ordered earlier in the admission.

Scenario 3: Post-CABG monitoring on consecutive days

A 67-year-old female is 2 days post-CABG. The surgeon orders daily CK-MB to screen for perioperative MI. Labs are drawn on two consecutive days.

Correct coding: 82553 on day 1 and 82553 on day 2, each as a single unit. Supporting diagnoses: I97.190 (other postprocedural cardiac functional disturbances) or Z48.812 (surgical aftercare following surgery on the circulatory system).

Why: Different dates of service do not require Modifier 91. Each day's draw is a standalone service within the MUE limit of 3 per date. No modifier is needed to bill these as separate daily services.

Scenario 4: Rhabdomyolysis with cardiac differentiation

A 35-year-old marathon runner presents with severe myalgia and dark urine. Total CK (82550) is markedly elevated. The physician separately orders CK-MB to determine whether cardiac involvement is present.

Correct coding: 82550 plus 82553, with Modifier 59 appended to 82553 if the payer has a bundling edit pairing the two codes. Supporting diagnosis: M62.82 (rhabdomyolysis).

Why: Both tests serve distinct clinical purposes: total enzyme quantity versus cardiac fraction source identification. Verify NCCI PTP edit status between 82550 and 82553 for the applicable payer before deciding whether Modifier 59 is required.

Related Codes

• 82550: CK, total; ordered when total enzyme quantity is needed without fraction analysis
• 82552: CK, isoenzymes; full electrophoretic separation reporting MM, MB, and BB fractions
• 82554: CK, isoforms; isoform subtypes for precise injury timing; MUE = 1
• 84484: Troponin, quantitative; preferred primary ACS biomarker; commonly ordered alongside 82553 in cardiac panels
• 84512: Troponin, qualitative; rapid point-of-care troponin screen
• 83874: Myoglobin; earlier-rising muscle injury marker; sometimes ordered with CK-MB in acute cardiac workups
• I21.4: NSTEMI; primary supporting diagnosis for acute cardiac biomarker testing
• R07.9: Chest pain, unspecified; common presenting diagnosis supporting medical necessity before AMI confirmation

Sources {#sources}

1. Coding Ahead CPT Database, code 82553: official description, MUE (3), CLIA waived status (No), Statutory Exclusion from MPFS, APC indicator (Conditionally packaged laboratory tests), code history (added 1993, short description revised 2011). Verified 2026-03-18.
2. Coding Ahead CPT Database, codes 82550, 82552, 82554, 84484, 84512, 83874: descriptions, MUEs, CLIA waived status. Verified 2026-03-18.